Erratum to: The porphyrias: Pathophysiology(Intern Emerg Med, (2010), 5, Suppl 1 (S65-S71), 10.1007/s11739-010-0452-z);The porphyrias: Pathophysiology

Internal and Emergency Medicine

Volumn 5, Issue SUPPL. 1, 2010, Pages 65-71

  Pietrangelo, Antonello ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Aminolevulinic acid; Haem disorders; Hereditary diseases; Porphobilinogen; Porphyrins; Uroporphyrins

Indexed keywords

EID: 77957223607     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0571-1     Document Type: Erratum

References (29)

1. Puy H, Gouya L, Deybach JC (2010) Porphyrias. Lancet 375: 924-937.
2. Moore MR (1998) The biochemistry of heme synthesis in porphyria and in the porphyrinurias. Clin Dermatol 16: 203-223.
3. Fraser DJ, Podvinec M, Kaufmann MR, Meyer UA (2002) Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem 277: 34717-34726.
4. Smith SJ, Cox TM (1997) Translational control of erythroid delta-aminolevulinate synthase in immature human erythroid cells by heme. Cell Mol Biol (Noisy-le-grand) 43: 103-114.
5. Sassa S, Kappas A (2000) Molecular aspects of the inherited porphyrias. J Intern Med 247: 169-178.
6. Erskine PT, Norton E, Cooper JB et al (1999) X-ray structure of 5-aminolevulinic acid dehydratase from Escherichia coli complexed with the inhibitor levulinic acid at 2. 0 A resolution. Biochemistry 38: 4266-4276.
7. Sassa S (1998) ALAD porphyria. Semin Liver Dis 18: 95-101.
8. Ventura P, Cappellini MD, Rocchi E (2009) The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med 4: 297-308.
9. Thunell S, Floderus Y, Henrichson A, Harper P (2006) Porphyria in Sweden. Physiol Res 55(Suppl 2): S109-S118.
10. Chretien S, Dubart A, Beaupain D et al (1988) Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA 85: 6-10.
11. Grandchamp B, Puy H, Lamoril J, Deybach JC, Nordmann Y (1996) Review: molecular pathogenesis of hepatic acute porphyrias. J Gastroenterol Hepatol 11: 1046-1052.
12. Martinez di Montemuros F, Di Pierro E, Biolcati G et al (2001) Acute intermittent porphyria: heterogeneity of mutations in the hydroxymethylbilane synthase gene in Italy. Blood Cells Mol Dis 27: 961-970.
13. Brownlie PD, Lambert R, Louie GV et al (1994) The three-dimensional structures of mutants of porphobilinogen deaminase: toward an understanding of the structural basis of acute intermittent porphyria. Protein Sci 3: 1644-1650.
14. Ged C, Moreau-Gaudry F, Richard E, Robert-Richard E, de Verneuil H (2009) Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. Cell Mol Biol (Noisy-le-grand) 55: 53-60.
15. Desnick RJ, Glass IA, Xu W, Solis C, Astrin KH (1998) Molecular genetics of congenital erythropoietic porphyria. Semin Liver Dis 18: 77-84.
16. Elder GH (1998) Porphyria cutanea tarda. Semin Liver Dis 18: 67-75.
17. Fargion S, Fracanzani AL (2003) Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J Hepatol 39: 635-638.
18. Rocchi E, Gibertini P, Cassanelli M et al (1986) Hepatitis B virus infection in porphyria cutanea tarda. Liver 6: 153-157.
19. Cappellini MD, Martinez di Montemuros F, Tavazzi D et al (2001) Seven novel point mutations in the uroporphyrinogen decarboxylase (UROD) gene in patients with familial porphyria cutanea tarda (f-PCT). Hum Mutat 17: 350.
20. Fargion S, Fracanzani AL, Romano R et al (1996) Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: possible explanation for iron overload. J Hepatol 24: 564-569.
21. Takahashi S, Taketani S, Akasaka JE et al (1998) Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Blood 92: 3436-3444.
22. Rocchi E, Pietrangelo A, Gibertini P et al (1984) Hereditary coproporphyria. A familial study. Recenti Prog Med 75: 123-131.
23. Lee DS, Flachsova E, Bodnarova M et al (2005) Structural basis of hereditary coproporphyria. Proc Natl Acad Sci USA 102: 14232-14237.
24. Di Pierro E, Ventura P, Brancaleoni V et al (2009) Clinical, biochemical and genetic characteristics of variegate porphyria in Italy. Cell Mol Biol (Noisy-le-grand) 55: 79-88.
25. Hift RJ, Meissner PN, Corrigall AV et al (1997) Variegate porphyria in South Africa, 1688-1996--new developments in an old disease. S Afr Med J 87: 722-731.
26. Meissner PN, Dailey TA, Hift RJ et al (1996) A R59 W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 13: 95-97.
27. Rufenacht UB, Gouya L, Schneider-Yin X et al (1998) Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet 62: 1341-1352.
28. Martinez di Montemuros F, Di Pierro E, Patti E et al (2002) Molecular characterization of porphyrias in Italy: a diagnostic flow-chart. Cell Mol Biol (Noisy-le-grand) 48: 867-876.
29. Schneider-Yin X, Rufenacht UB, Hergersberg M et al (2001) Haplotype analysis in determination of the heredity of erythropoietic protoporphyria among Swiss families. J Invest Dermatol 117: 1521-1525.